Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma

Kyriakos P. Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, Jason Jiang, Weiliang Shi, Frauke Bentzien, Drew Rasco, Pau Abrisqueta, Julie M. Vose, Josep Tabernero

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences